Atofab® contains the active substance atomoxetine and is used to treat attention deficit hyperactivity disorder (ADHD).
It is given to adults, adolescents and children aged 6 years and older.
Atomoxetine is used as part of a comprehensive treatment programme for this disorder, but also requires non-drug interventions such as counselling and behavioural therapy.
It is not intended for ADHD treatment in children under 6 years of age, as the efficacy and safety of the medicine in this patient group are not known.
In adults, ADHD treatment with Atofab® is indicated if the signs of the disease are very distressing and affect the patient’s professional or social life, and if the ADHD signs were already present in childhood.
|10 mg||10, 30|
|18 mg||10, 30|
|25 mg||10, 30|
|40 mg||10, 30|
|60 mg||10, 30|